CO2019010860A2 - A liquid formulation of antibody against tnf alpha - Google Patents

A liquid formulation of antibody against tnf alpha

Info

Publication number
CO2019010860A2
CO2019010860A2 CONC2019/0010860A CO2019010860A CO2019010860A2 CO 2019010860 A2 CO2019010860 A2 CO 2019010860A2 CO 2019010860 A CO2019010860 A CO 2019010860A CO 2019010860 A2 CO2019010860 A2 CO 2019010860A2
Authority
CO
Colombia
Prior art keywords
liquid formulation
antibody against
tnf alpha
against tnf
alpha
Prior art date
Application number
CONC2019/0010860A
Other languages
Spanish (es)
Inventor
Sora Yun
Youn Kyung Ko
Jin Eon So
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019010860(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CO2019010860A2 publication Critical patent/CO2019010860A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una formulación líquida de un anticuerpo contra TNF-α, específicamente a una formulación líquida de adalimumab.The present invention relates to a liquid formulation of an antibody against TNF-α, specifically to a liquid formulation of adalimumab.

CONC2019/0010860A 2017-03-16 2019-09-30 A liquid formulation of antibody against tnf alpha CO2019010860A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (en) 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibody

Publications (1)

Publication Number Publication Date
CO2019010860A2 true CO2019010860A2 (en) 2020-01-17

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0010860A CO2019010860A2 (en) 2017-03-16 2019-09-30 A liquid formulation of antibody against tnf alpha

Country Status (15)

Country Link
JP (2) JP7109849B2 (en)
KR (2) KR20180106974A (en)
CN (1) CN110621303A (en)
AU (1) AU2018236651B2 (en)
BR (1) BR112019019162A2 (en)
CO (1) CO2019010860A2 (en)
MA (1) MA46988A1 (en)
MX (1) MX2019010895A (en)
MY (1) MY197202A (en)
NZ (1) NZ757965A (en)
PH (1) PH12019502075A1 (en)
RU (1) RU2756619C2 (en)
UA (1) UA123847C2 (en)
WO (1) WO2018169348A1 (en)
ZA (1) ZA201906696B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3129901A1 (en) * 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
TW202102260A (en) * 2019-03-21 2021-01-16 美商再生元醫藥公司 Stabilized formulations containing anti-il-33 antibodies
WO2021164717A1 (en) * 2020-02-20 2021-08-26 百奥泰生物制药股份有限公司 ANTI-TNF-α ANTIBODY PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2637690T3 (en) * 2010-11-11 2017-03-31 Abbvie Biotechnology Ltd HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
WO2013164837A1 (en) * 2012-03-07 2013-11-07 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
KR102362829B1 (en) 2012-09-07 2022-02-15 코히러스 바이오사이언시즈, 인코포레이티드 Stable aqueous formulations of adalimumab
JP2016505633A (en) 2013-01-24 2016-02-25 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ TNFα antigen binding protein
AR095496A1 (en) 2013-03-15 2015-10-21 Bayer Healthcare Llc FORMULATIONS OF ANTIBODIES ANTI-RECEIVER OF PROLACTIN
US20150274819A1 (en) 2014-03-03 2015-10-01 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
WO2015151115A1 (en) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
ES2600488T3 (en) * 2014-05-23 2017-02-09 Ares Trading S.A. Liquid pharmaceutical composition
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (en) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Pharmaceutical anti-tnfalpha antibody formulation
WO2016120413A1 (en) * 2015-01-28 2016-08-04 Mabxience S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody

Also Published As

Publication number Publication date
JP7109849B2 (en) 2022-08-01
KR20180106974A (en) 2018-10-01
JP2022097600A (en) 2022-06-30
WO2018169348A1 (en) 2018-09-20
BR112019019162A2 (en) 2020-04-14
AU2018236651B2 (en) 2020-12-10
MY197202A (en) 2023-05-31
PH12019502075A1 (en) 2020-09-14
RU2019130728A (en) 2021-04-16
RU2019130728A3 (en) 2021-04-16
CN110621303A (en) 2019-12-27
KR20200096472A (en) 2020-08-12
NZ757965A (en) 2022-07-01
UA123847C2 (en) 2021-06-09
MX2019010895A (en) 2019-11-05
JP2020510079A (en) 2020-04-02
MA46988A1 (en) 2020-06-30
AU2018236651A1 (en) 2019-10-31
ZA201906696B (en) 2020-08-26
RU2756619C2 (en) 2021-10-04
KR102342292B1 (en) 2021-12-24

Similar Documents

Publication Publication Date Title
ECSP18007905A (en) MONOCLONAL ANTIBODIES AGAINST BCMA
CL2018001488A1 (en) Aqueous pharmaceutical formulation of the anti-pd-l1 avelumab antibody
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
MD3827845T2 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
CL2016002455A1 (en) Multispecific antibodies.
EA201791029A1 (en) ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION
MY198059A (en) Anti-ox40 antibodies and their uses
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
BR112018074468A2 (en) anti-cd40 antibodies and their uses
BR112017008666A2 (en) anti-fgfr2 / 3 antibodies and methods of use
EA201691610A1 (en) ANTI-JAGGED1 ANTIBODIES AND METHODS OF APPLICATION
CO2019010860A2 (en) A liquid formulation of antibody against tnf alpha
BR112017015880A2 (en) antibodies, uses and methods
CL2017002055A1 (en) Liquid sample
EA201992027A1 (en) WATER COMPOSITION OF ANTIBODIES AGAINST PD-L1
BR112018002382A8 (en) NEW HUMAN ANTI-GVPI ANTIBODIES AND THEIR USES
TWD192262S (en) Infusion Pump
UY36107A (en) MICROENCAPSULATED COMPOSITION INHIBITING NITRIFICATION
BR112016027455A2 (en) ppar modulators
CL2017001957U1 (en) Male urinary pad
EP3738091A4 (en) Utilizing social engagement to generate metagaming resources
EA201792266A1 (en) METHOD OF OBTAINING A COMPOUND ON THE BASIS OF MERCURY, A CONNECTION ON THE BASIS OF MERCURY, METHODS OF APPLICATION OF THE CONNECTION BASED ON MERCURY AND APPLICATION OF THE CONNECTION BASED ON MERCURY
MA39411A (en) SUMMARY OF THE ENANTIOMER OF PROGESTERONE AND ITS INTERMEDIARIES
CL2017003414S1 (en) Solar kettle
CL2019000555S1 (en) Blender.